Heart failure with preserved ejection fraction phenogroup classification using machine learning.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
06 2023
Historique:
revised: 05 01 2023
received: 09 04 2022
accepted: 13 03 2023
medline: 19 5 2023
pubmed: 14 4 2023
entrez: 13 4 2023
Statut: ppublish

Résumé

Heart failure (HF) with preserved ejection fraction (HFpEF) is a complex syndrome with a poor prognosis. Phenotyping is required to identify subtype-dependent treatment strategies. Phenotypes of Japanese HFpEF patients are not fully elucidated, whose obesity is much less than Western patients. This study aimed to reveal model-based phenomapping using unsupervised machine learning (ML) for HFpEF in Japanese patients. We studied 365 patients with HFpEF (left ventricular ejection fraction >50%) as a derivation cohort from the Nara Registry and Analyses for Heart Failure (NARA-HF), which registered patients with hospitalization by acute decompensated HF. We used unsupervised ML with a variational Bayesian-Gaussian mixture model (VBGMM) with common clinical variables. We also performed hierarchical clustering on the derivation cohort. We adopted 230 patients in the Japanese Heart Failure Syndrome with Preserved Ejection Fraction Registry as the validation cohort for VBGMM. The primary endpoint was defined as all-cause death and HF readmission within 5 years. Supervised ML was performed on the composite cohort of derivation and validation. The optimal number of clusters was three because of the probable distribution of VBGMM and the minimum Bayesian information criterion, and we stratified HFpEF into three phenogroups. Phenogroup 1 (n = 125) was older (mean age 78.9 ± 9.1 years) and predominantly male (57.6%), with the worst kidney function (mean estimated glomerular filtration rate 28.5 ± 9.7 mL/min/1.73 m ML could successfully stratify Japanese HFpEF patients into three phenogroups (atherosclerosis and chronic kidney disease, atrial fibrillation, and younger and left ventricular hypertrophy groups).

Identifiants

pubmed: 37051638
doi: 10.1002/ehf2.14368
pmc: PMC10192264
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2019-2030

Informations de copyright

© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

ESC Heart Fail. 2023 Jun;10(3):2019-2030
pubmed: 37051638
N Engl J Med. 2020 Oct 8;383(15):1436-1446
pubmed: 32970396
J Cardiol. 2013 Apr;61(4):260-6
pubmed: 23403369
Circulation. 2021 Jan 12;143(2):120-134
pubmed: 33118835
J Am Coll Cardiol. 2014 Oct 28;64(17):1765-74
pubmed: 25443696
Circulation. 2015 Jan 20;131(3):269-79
pubmed: 25398313
Circulation. 2021 Apr 6;143(14):1377-1390
pubmed: 33554614
Eur J Heart Fail. 2015 Sep;17(9):925-35
pubmed: 26250359
JAMA. 2019 Sep 17;322(11):1085-1095
pubmed: 31475295
Eur Heart J. 2014 Oct 21;35(40):2797-815
pubmed: 25104786
JACC Heart Fail. 2020 Mar;8(3):172-184
pubmed: 31926856
Circ J. 2019 Apr 25;83(5):1019-1024
pubmed: 30842361
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Am Heart J. 2022 Dec;254:112-121
pubmed: 36007566
J Physiol. 2021 Nov;599(22):4991-5013
pubmed: 34510457
IEEE Trans Cybern. 2021 Jul;51(7):3616-3629
pubmed: 33232256
Circ Heart Fail. 2011 Sep;4(5):569-77
pubmed: 21715583
Int J Comput Assist Radiol Surg. 2016 Nov;11(11):1937-1949
pubmed: 27289240
Int J Med Robot. 2020 Apr;16(2):e2058
pubmed: 31713318
Circ J. 2018 May 25;82(6):1534-1545
pubmed: 29576598
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
Circ Heart Fail. 2021 Apr;14(4):e007901
pubmed: 33866828
Eur J Heart Fail. 2020 Jan;22(1):148-158
pubmed: 31637815
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
JAMA. 2019 Apr 2;321(13):1261-1274
pubmed: 30874766
N Engl J Med. 2006 Jul 20;355(3):251-9
pubmed: 16855265
Exp Ther Med. 2019 Mar;17(3):2129-2136
pubmed: 30867700

Auteurs

Atsushi Kyodo (A)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Koshiro Kanaoka (K)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Ayaka Keshi (A)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Maki Nogi (M)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Kazutaka Nogi (K)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Satomi Ishihara (S)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Daisuke Kamon (D)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Yukihiro Hashimoto (Y)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Yasuki Nakada (Y)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Tomoya Ueda (T)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Ayako Seno (A)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Taku Nishida (T)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Kenji Onoue (K)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Tsuneari Soeda (T)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Rika Kawakami (R)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Makoto Watanabe (M)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Toshiyuki Nagai (T)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Toshihisa Anzai (T)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Yoshihiko Saito (Y)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH